Arvinas

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapeutics using PROTAC (proteolysis-targeting chimera) technology. It designs small molecules that selectively induce degradation of disease-causing proteins rather than merely inhibiting them, with a focus on oncology and other protein-driven diseases. Arvinas advances multiple clinical-stage product candidates and partners with other biopharma companies to expand its degrader platform and bring first‑in‑class therapies to patients.